CharlesLouisWisemanMDFACP, QME
Oncology • Beverly Hills, CAFounder and Director, Briacell Therapeutics Corp
Dr. Wiseman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
8900 Wilshire Blvd, Second Floor
Beverly Hills, CA 90211Phone+1 323-377-4741Fax+1 626-577-9069- Is this information wrong?
Education & Training
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1975 - 1976- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterResidency, Hematology and Medical Oncology, 1972 - 1973
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1970 - 1972
University of Utah HealthInternship, Transitional Year, 1969 - 1970
David Geffen School of Medicine at UCLAClass of 1969
Certifications & Licensure
CA State Medical License 1971 - 2024
FL State Medical License 2016 - 2018
TX State Medical License 1973 - 1980
LA State Medical License 1974 - 1975
Awards, Honors, & Recognition
- Founder and Director BriaCell Therapeutics, 2014-2016
Clinical Trials
- Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer Start of enrollment: 1991 Apr 01
- Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers Start of enrollment: 2004 Nov 01
Publications & Presentations
PubMed
- 8 citationsObjective Clinical Regression of Metastatic Breast Cancer in Disparate Sites after Use of Whole-Cell Vaccine Genetically Modified to Release SargramostimCharles Wiseman, Alex Kharazi> ;The Breast Journal. 2006 Sep 1
- 230 citationsA Validated Mathematical Model of Cell-Mediated Immune Response to Tumor GrowthLisette G de Pillis, Ami Radunskaya, Charles L. Wiseman> ;Cancer Research. 2005 Sep 1
- 13 citationsPhorbol myristate acetate and Bryostatin 1 rescue IFN-gamma inducibility of MHC class II molecules in LS1034 colorectal carcinoma cell line.Yuri Kudinov, Charles Wiseman, A. I. Kharazi> ;Cancer Cell International. 2003 Mar 25
- Join now to see all
Press Mentions
With Pandemic in Rearview Mirror, BriaCell Charges Ahead with Cancer ImmunotherapyApril 24th, 2023- BriaCell Presents Clinical Findings at 2020 American Society of Clinical Oncology (ASCO) MeetingMay 29th, 2020
BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson HealthFebruary 11th, 2020- Join now to see all
Hospital Affiliations
Cedars-Sinai Medical CenterLos Angeles, California- St. Vincent Medical CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
